Drug Safety

, Volume 29, Issue 10, pp 926–926 | Cite as

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

  • J. Cobert
  • G. L. C. Ferreira
  • L. Wilton
  • S. A. W. Shakir
Abstracts

Keywords

Fluoxetine Paroxetine Sertraline Venlafaxine Fluvoxamine 

References

  1. 1.
    Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 1998 Mar; 13(2): 63–73PubMedCrossRefGoogle Scholar
  2. 2.
    Hartmann PM. Mirtazapine: a newer antidepressant. Am Fam Physician 1999 Jan 1; 59(1): 159–61PubMedGoogle Scholar
  3. 3.
    Shakir SAW. Prescription-Event Monitoring. In: Strom B, editor. Pharmacoepidemiology. 4th ed. Chichester, UK: John Wiley & Sons Ltd, 2005: 203–16Google Scholar
  4. 4.
    Shakir SAW. Causality and Correlation in Pharmacovigilance. In: Waller P, Talbot J, editors. Stephens’ Detection of New Adverse Drug Reactions. 5th ed. Chichester, UK: John Wiley & Sons Ltd, 2004: 330–43Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • J. Cobert
    • 1
  • G. L. C. Ferreira
    • 1
    • 2
  • L. Wilton
    • 1
    • 2
  • S. A. W. Shakir
    • 1
    • 2
  1. 1.Drug Safety Research UnitSouthamptonUK
  2. 2.University of PortsmouthPortsmouthUK

Personalised recommendations